Development of lipid-based nanoparticles for enhancing the oral bioavailability of paclitaxel D Pandita, A Ahuja, V Lather, B Benjamin, T Dutta, T Velpandian, RK Khar Aaps Pharmscitech 12, 712-722, 2011 | 111 | 2011 |
Simple method for the determination of rosiglitazone in human plasma using a commercially available internal standard RNVS Mamidi, B Benjamin, M Ramesh, NR Srinivas Biomedical Chromatography 17 (6), 417-420, 2003 | 46 | 2003 |
HPLC method for determination of rosiglitazone in human plasma and its application in a clinical pharmacokinetic study, RR Rao N. V. S. Mamidi, Madhusudana R. Chaluvadi, Biju Benjamin, Mullangi ... Arzneimittelforschung 52 (7), 560-564, 2002 | 35 | 2002 |
Enhanced expression of recombinant proteins utilizing a modified baculovirus expression vector P Tiwari, S Saini, S Upmanyu, B Benjamin, R Tandon, KS Saini, S Sahdev Molecular biotechnology 46, 80-89, 2010 | 26 | 2010 |
RBx-0597, a potent, selective and slow-binding inhibitor of dipeptidyl peptidase-IV for the treatment of type 2 diabetes S Singh, S Sethi, V Khanna, B Benjamin, R Kant, J Sattigeri, VS Bansal, ... European journal of pharmacology 652 (1-3), 157-163, 2011 | 20 | 2011 |
Approaches towards the development of chimeric DPP4/ACE inhibitors for treating metabolic syndrome JA Sattigeri, S Sethi, JA Davis, S Ahmed, GV Rayasam, BG Jadhav, ... Bioorganic & Medicinal Chemistry Letters 27 (11), 2313-2318, 2017 | 19 | 2017 |
Integration of physicochemical and pharmacokinetic parameters in lead optimization: a physiological pharmacokinetic model based approach B Benjamin, T Kanta Barman, T Chaira, J K Paliwal Current Drug Discovery Technologies 7 (3), 143-153, 2010 | 17 | 2010 |
The observed correlation between in vivo clinical pharmacokinetic parameters and in vitro potency of VEGFR-2 inhibitors B Benjamin, M Sahu, U Bhatnagar, D Abhyankar, NR Srinivas Arzneimittelforschung 62 (04), 194-201, 2012 | 14 | 2012 |
Hematological effects of non-homogenous ionizing radiation exposure in a non-human primate model IL Jackson, A Gibbs, Y Poirier, L Wathen, J Eley, E Draeger, ... Radiation Research 191 (5), 428-438, 2019 | 8 | 2019 |
Biological evaluation of RBx-0128, a potent and selective dipeptidyl peptidase-IV inhibitor in type 2 diabetes genetic model JA Davis, PS Kumar, S Singh, A Surender, S Roy, V Khanna, S Sethi, ... Indian Journal of Pharmacology 44 (6), 759-764, 2012 | 3 | 2012 |
Highly sensitive method for the determination of JI‐101, a multi‐kinase inhibitor in human plasma and urine by LC‐MS/MS‐ESI: method validation and application to a clinical … S Sharma, NK Dubey, AK Dasgupta, M Sahu, B Benjamin, R Mullangi, ... Biomedical Chromatography 26 (2), 232-238, 2012 | 3 | 2012 |
A drug–drug interaction study of everolimus (an mTOR inhibitor) and JI-101, an orally active inhibitor of VEGF 2, PDGF, and EphB4 receptors, in patients with advanced urologic … N Agarwal, M Sahu, DJ Abhyankar, TL Werner, B Benjamin, NR Srinivas, ... Journal of Clinical Oncology 29 (15_suppl), e15077-e15077, 2011 | 3 | 2011 |
PB2258: PHASE 1 FIRST IN HUMAN STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND EFFICACY OF GRC54276, A NOVEL HPK1 THRONINE-KINASE INHIBITOR, IN ADVANCED SOLID … H Doddihal, T Marron, CT Satheesh, M Avaronnan, R Nagarkar, ... HemaSphere 7 (S3), e56696bb, 2023 | | 2023 |
Novel Methodology Integrating Experimental ADME and Physicochemical Data for Rational Lead Optimization Using Selected Clinical Compounds B Benjamin Pilani, 2012 | | 2012 |
Identification of novel orally active dipeptidyl peptidase IV inhibitor 7E8E80B, equipotent and equi-efficaceous to Januvia (TM) JA Davis, S Singh, S Roy, S Sundaram, S Sethi, B Benjamin, A Surender, ... INDIAN JOURNAL OF PHARMACOLOGY 40, 174-174, 2008 | | 2008 |
Open access generic method for continous determination of major human CYP 450 probe substrates/metabolites and its application in drug metabolism studies NRS M.N.V.S.Rao, B.Biju, A.K.Ansar, M.Ramesh Xenobiotica 33 (12), 1233-1245, 2003 | | 2003 |